Neuroscientific Biopharmaceuticals (ASX:NSB) EV-to-EBIT : 3.82 (As of May. 12, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Neuroscientific Biopharmaceuticals EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Neuroscientific Biopharmaceuticals's Enterprise Value is A$3.17 Mil. Neuroscientific Biopharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.83 Mil. Therefore, Neuroscientific Biopharmaceuticals's EV-to-EBIT for today is 3.82.

The historical rank and industry rank for Neuroscientific Biopharmaceuticals's EV-to-EBIT or its related term are showing as below:

ASX:NSB' s EV-to-EBIT Range Over the Past 10 Years
Min: -34.3 Med: 0 Max: 7.48
Current: 3.82

During the past 5 years, the highest EV-to-EBIT of Neuroscientific Biopharmaceuticals was 7.48. The lowest was -34.30. And the median was 0.00.

ASX:NSB's EV-to-EBIT is ranked better than
57.74% of 433 companies
in the Biotechnology industry
Industry Median: 9.43 vs ASX:NSB: 3.82

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Neuroscientific Biopharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was A$3.03 Mil. Neuroscientific Biopharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.83 Mil. Neuroscientific Biopharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 27.46%.

Neuroscientific Biopharmaceuticals EV-to-EBIT Historical Data

The historical data trend for Neuroscientific Biopharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuroscientific Biopharmaceuticals EV-to-EBIT Chart

Neuroscientific Biopharmaceuticals Annual Data

Trend

Jun19

Jun20

Jun21

Jun22

Jun23

EV-to-EBIT

-3.61

-4.05

-10.67

-1.77

-6.17

Neuroscientific Biopharmaceuticals Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial							-	-1.77	-	-6.17	-

Competitive Comparison of Neuroscientific Biopharmaceuticals's EV-to-EBIT

For the Biotechnology subindustry, Neuroscientific Biopharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neuroscientific Biopharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neuroscientific Biopharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Neuroscientific Biopharmaceuticals's EV-to-EBIT falls into.

Neuroscientific Biopharmaceuticals EV-to-EBIT Calculation

Neuroscientific Biopharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	3.171	/	0.831
	=	3.82

Neuroscientific Biopharmaceuticals's current Enterprise Value is A$3.17 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Neuroscientific Biopharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.83 Mil.

Neuroscientific Biopharmaceuticals (ASX:NSB) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Neuroscientific Biopharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	0.831	/	3.02662
	=	27.46 %

Neuroscientific Biopharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was A$3.03 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Neuroscientific Biopharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.83 Mil.

Neuroscientific Biopharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Neuroscientific Biopharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Neuroscientific Biopharmaceuticals (ASX:NSB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuroscientific Biopharmaceuticals Ltd (ASX:NSB) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

85 Forrest Street, Suite 5, Cottesloe, Perth, WA, AUS, 6011

Website

https://www.neuroscientific.com

Neuroscientific Biopharmaceuticals Ltd is an Australian-based biotechnology company. The company is engaged in the development of diagnostic and therapeutic treatments for neurodegenerative diseases through preclinical studies of patented technologies.

Neuroscientific Biopharmaceuticals (ASX:NSB) Headlines

No Headlines